Analysts’ Top Healthcare Picks: Trulieve Cannabis (TCNNF), Medline (MDLN)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Trulieve Cannabis (TCNNF – Research Report) and Medline (MDLN – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Trulieve Cannabis (TCNNF)
In a report issued on February 27, Frederico Gomes from ATB Cormark Capital Markets maintained a Buy rating on Trulieve Cannabis, with a price target of C$15.00. The company’s shares closed last Monday at $6.06.
According to TipRanks.com, Gomes is a 1-star analyst with an average return of
Currently, the analyst consensus on Trulieve Cannabis is a Strong Buy with an average price target of $14.99, implying a 134.6% upside from current levels. In a report issued on February 26, Haywood also maintained a Buy rating on the stock with a C$19.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Medline (MDLN)
In a report released today, Brandon Vazquez from William Blair maintained a Buy rating on Medline. The company’s shares closed last Monday at $46.43.
According to TipRanks.com, Vazquez is a 2-star analyst with an average return of
Medline has an analyst consensus of Strong Buy, with a price target consensus of $51.88, implying a 10.1% upside from current levels. In a report issued on February 27, TipRanks – Google also initiated coverage with a Buy rating on the stock with a $56.00 price target.
